

March 27, 2020

# Covid-19 adds to sector woes...

The domestic auto industry is going through difficult times, with industry sales volumes down nearly 16% YTDFY20. The industry was already in a transitory phase for the upcoming switchover to BS-VI norms with effect from April 1, 2020 that needed intense deliberation and strategising in areas related to products, pricing, production & inventory management. We were factoring in negative growth in Q1FY21, a neutral Q2FY21 and higher single digit growth in H2FY21 to finally end the year positive with ~5% industry growth for FY21. However, the recent outbreak of Covid-19 with associated nationwide lockdowns as well as plant closures of the entire ecosystem (auto OEM + auto ancillary) will meaningful change our estimates.

# Rework estimates to build in delay in recovery...

As per SIAM estimates, the present suspension of production activities at OEMs and ancillaries would cost the industry ~₹ 2,300 crore/day in lost revenues. Q4FY20 (till March 15) was witness to production rationalisation at most OEMs as the focus remained firmly on rundown of BS-IV stock. With half of March slated to be a washout, the quarter is another poor one. Going forward, we expect industry volumes to decline sharply (~40-50%) in Q1FY21E amid plant closures, accounting for at least two months of subnormal operations (one month of complete closure i.e. April 2020 and corresponding one month of gradual resumption of work i.e. May 2020). Our reworked estimates bake in another year of de-growth at the industry level in FY21E (-5%), after adjusting for some pent up recovery in H2FY21E. We see meaningful growth returning to the industry only in FY22E post normalisation of BS-VI environment, expected uptick in economic activity and consumer spending and build in ~10% volume increase for that year.

# Indian automobile industry leads by example!

The auto industry has stepped forward as a responsible stakeholder in this time of unprecedented crisis affecting the length and breadth of the country. The industry is one of the top tax contributors to the exchequer (our estimates suggest auto space accounts for ~8-10% of the total direct and indirect tax collected in India with GST collection itself pegged at ~₹ 1.5 lakh crore) and has assured commitment for supporting the most vulnerable section of its employees in the immediate future in aspects of job security and work compensation. Several OEMs have offered to manufacture vital requirements like ventilators and masks. Recent announcements of voluntary salary cuts by some senior managements are a welcome gesture that expresses their solidarity during prevailing tough business conditions. Domestic auto OEMs possess healthy B/S with adequate capital to support its staff in the present difficult times.

### Valuation & Outlook

In the present times of despair and unprecedented economic slowdown due a Black Swan event like Covid-19 outbreak, we reiterate our preference for business models that are capital efficient in nature (RoE, RoCE >15%), possess healthy balance sheet (debt: equity < 0.5x) and are more domestic (India) centric in nature. We maintain our view that these businesses remain better placed to navigate the current downturn effectively and emerge stronger from it, leaving themselves primed for eventual recovery down the road. Among OEMs, we have valuation comfort and assign BUY rating to Hero MotoCorp, M&M, Bajaj Auto & Ashok Leyland while assigning HOLD rating to the rest of the pack i.e. Maruti Suzuki, Tata Motors, Eicher Motors and Escorts. Among ancillaries, we assign BUY rating to Exide Industries and HOLD rating to Apollo Tyres and Bharat Forge.

ICICI Direct Auto coverage universe									
Company	Rating	CMP	Target price	Potential upside					
Maruti Suzuki	Hold	5,000	4,800	-4%					
Tata Motors	Hold	75	85	13%					
M&M	Buy	290	400	38%					
Ashok Leyland	Buy	45	55	22%					
Hero Motocorp	Buy	1,750	2,110	21%					
Bajaj Auto	Buy	2,110	2,500	18%					
Eicher Motors	Hold	15,000	16,870	12%					
Escorts	Hold	675	740	10%					
Exide Industries	Buy	130	160	23%					
Apollo Tyres	Hold	85	90	6%					
Bharat Forge	Hold	285	320	12%					

Recommend BUY on domestic market oriented business models viz. Ashok Leyland, Bajaj Auto, Hero MotoCorp, M&M and Exide Industries

#### **Research Analysts**

Shashank Kanodia, CFA jaimin.desai@icicisecurities.com

Jaimin Desai jaimin.desai@icicisecurities.com

# Impact on I-Direct auto & auto ancillary coverage universe

### Maruti Suzuki (MSIL)

India's largest PV maker has been consistently outperforming not just its segment but the wider automotive industry as well on the volume front over the past six months. The company's proactiveness in introduction of BS-VI models well in advance of the mandated switchover has been key to its resilience, with popular models retaining their consumer appeal even in the upgraded versions. MSIL has closed all plant activities in Manesar and Gurugram (Haryana) until further government notice, with Suzuki Motor Gujarat (SMG) production halted till April 14. While plant and showroom closures would affect March, April and possibly May performance (as things stand), we believe the company remains best placed to stage a swifter recovery than most other OEMs courtesy having no unsold BS-IV stock on books and demonstrated acceptance of BS-VI models on the ground.

For MSIL, we build -13%, flat, 10.8% YoY volume trajectory in FY20E, FY21E, FY22E, respectively. Upgrading the stock to **HOLD**, we value it at ₹ 4,800 i.e. 20x P/E on FY22E EPS of ₹ 240/share.

We expect MSIL to clock total sales volume of 17.85 lakh units in FY22E vs. 16.22 lakh units in FY20E and 18.62 lakh units in FY19.

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20-22E)
Net Sales	79,762.7	86,020.3	78,476.7	77,344.0	86,910.3	5.29
E B IT D A	12,061.5	10,999.3	7,919.0	7,841.3	9,537.4	9.79
EBITDA Margins (%)	15.1	12.8	10.1	10.1	11.0	
Net Profit	7,721.8	7,500.6	5,969.2	6,058.1	7,257.7	10.39
EPS (₹)	255.6	248.3	197.6	200.5	240.3	
P/E	19.6	20.1	25.3	24.9	20.8	
RoNW (%)	18.5	16.3	12.1	11.5	12.6	
RoCE (%)	21.1	16.3	8.5	8.1	9.8	

Source: Company, ICICI Direct Research

### Hero MotoCorp (HMCL)

The 2-W segment is likely to be most affected by the issue of unsold BS-IV inventory as Covid-19 spread and preventive measures to tackle it force closure of dealerships in most parts of the country. Industry sources estimate ~5-7 lakh units of BS-IV stock lying with dealers at present. Market leader HMCL has, thus, appealed to the Supreme Court to allow registration of BS-IV vehicles citing the unprecedented and unforeseen nature of present circumstances. On its part, HMCL has halted production at all global facilities (India, Bangladesh, Colombia) until March 31. It has broadly underperformed its peers in 11MFY20 owing to limited presence in exports and weakness in scooters and entry level motorcycle segments. However, a dominant slant towards domestic business is now expected to work to its advantage in the short-term as both demand and supply legs take a hit globally.

For HMCL, we build in -17%, -8%, 10% YoY volume trajectory over FY20E, FY21E, FY22E, respectively. We retain our **BUY** rating on HMCL courtesy its healthy B/S and dividend payout (50%+). We also draw comfort from CFO yield >10%, FCF yield >5% and attractive dividend yield of  $\sim$ 5% at HMCL. We value HMCL at ₹ 2,110 i.e. 13x P/E on FY22E EPS of ₹ 162/share.

We expect HMCL to clock total sales volume of 66 lakh units in FY22E vs. 65 lakh units in FY20E and 78 lakh units in FY19

Exhibit 2: Revised financial su	innary for things					
Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-22E)
Net Sales	32,230.5	33,650.5	29,346.6	30,569.1	34,130.4	7.8%
E BITD A	5,280.2	4,929.8	4,226.7	3,748.2	4,496.4	3.1%
EBITD A Margins (%)	16.4	14.6	14.4	12.3	13.2	
Net P rofit	3,697.4	3,384.6	3,683.6	2,679.6	3,241.1	-6.2%
Normalised Net Profit	3,697.4	3,384.6	3,253.0	2,679.6	3,241.1	-0.2%
EPS (₹)	185.1	169.5	184.5	134.2	162.3	
P/E	9.5	10.3	9.5	13.0	10.8	
RoNW (%)	31.4	26.3	22.8	17.6	19.5	
RoCE (%)	42.4	37.1	27.9	22.7	25.3	

### Mahindra & Mahindra (M&M)

M&M has suspended production activities at all plants in Maharashtra in view of the heightened virus spread in the state. The company has been working hard on liquidating BS-IV stock over the past few months and had 3,500 units of unsold inventory as of March 22. With the BS-VI transition date upon us, M&M is likely to be one of the companies from our coverage universe to be affected as regards unsold inventory to an extent. Amid the ongoing nationwide lockdowns, ramp up of BS-VI production is expected to be gradual in nature, leading to a substantially weak Q1FY21E. Subsidiary SsangYong (domiciled in South Korea) has also seen 25-30% drop in domestic demand in February amid spread of virus in that country although its export performance was reported to be relatively unaffected. However, the tractor business is expected to fare better amid fewer demand concerns.

In the tractor division, we build in 2.4%, 7% YoY volume growth for FY21E, FY22E, while for automobile division, we build in -4%, 10% YoY volume trajectory for FY21E, FY22E, respectively. M&M trades at a significant discount to its earnings & investment holdings in B/S. We retain BUY on M&M with a revised target price of  $\stackrel{?}{<}$  400 using SOTP valuation methodology, valuing its base business at 5x EV/EBITDA on FY22E numbers.

The Mahindra group has also stepped forward as a responsible corporate house and offered to start work on making ventilators and masks for Covid19 patients at its manufacturing plants.

Total tractor sales are seen at 3.5 lakh units in FY22E vs. 3.06 lakh units in FY22E. Total automotive volumes are seen at 5.5 lakh units in FY22E vs. 5.2 lakh units in FY20E.

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E -22E)
Net Sales	48,685.6	53,614.0	48,039.2	50,320.6	55,646.3	7.6%
E BITD A	6,224.1	6,639.6	6,167.4	5,604.4	6,483.3	2.5%
EBITD A Margins (%)	12.8	12.4	12.8	11.1	11.7	
Net P rofit	4,356.0	4,796.1	4,708.0	3,413.6	4,021.5	-7.6%
Adjusted Net Profit	4,046.5	4,818.6	4,129.1	3,413.6	4,021.5	-1.3%
EPS (₹)	35.0	38.6	37.9	27.5	32.3	
P/E	8.3	7.5	7.7	10.6	9.0	
RoNW (%)	13.4	14.1	11.0	8.5	9.4	
RoCE (%)	16.6	16.7	13.3	10.6	11.7	

Source: Company, ICICI Direct Research

Valu	ration Matrix (SOTP)		
Automotive Business (UV +PV +CV +Tractors)	₹crore	₹/share	
Standalone business			
FY22E EBITDA	6,483		
Assigning EV/EBITDA Multiple of 5x	5.0		
Enterprise Value	32,416	261	
Net D ebt	(4,461)	-36	
Value of Standalone Business (A)	36,878	300	
Mahindra Vehicle Manufacturers Ltd			
Investment made by M&M (wholly owned subsidiary)	4,065		
Assigning 0.5x P/B on investment value	0.5		
Value of MV ML attributable to M& M (B)	2,033	16	
Total value of automobile business (C = A +B)		316	

Value of Investments (listed companies)	M& M stake	Estimated value	Contribution to M&M		Remark
	(%)	₹crore	₹crore	₹/share	
Tech Mahindra	26	48,807	12,719	102	C urrent market cap
M&M Financial Services	51	17,793	9,110	73	C urrent market cap
Mahindra Life space	52	1,026	529	4	C urrent market cap
Mahindra C IE	11	2,464	281.8	2	C urrent market cap
Mahindra Holidays & Resorts	67	2,000	1346.0	11	C urrent market cap
S sangYong Motors	75	1,200	900	7	C urrent market cap
O ther subsidiaries & investments			9,850	79	
Total Value of subsidiaries & associates (D)			34,735.5	280	
Value of investments post 70% holding company disc	ount (E = 0.7*D			84	
M&M Target Price (value of equity per share , C +E)				400	

Source: ICICI Direct Research

## Tata Motors (TML)

Tata Motors (TML) has been facing supply, demand related disruptions related to Covid-19 longer than other coverage universe OEMs courtesy its significant exposure to China. The virus outbreak comes at a particularly unfortunate time as the JLR business was just starting to experience clearance of overhangs around demand slump in China and Brexit related uncertainty. JLR's manufacturing facilities in China have resumed production from late February, albeit at reduced capacity. Covid-19 spread in Europe, however, has forced suspension of production in the UK (till April 20) and Slovakia. The company expects China related impact alone to result in 1% reduction in EBIT margins for FY20. Domestically, TML has been suffering from poor demand offtake on the M&HCV side (trucks in particular). Its focus has shifted to retail sales for liquidation of BS-IV inventory. Operations at its Chakan plant have been scaled down given the spread of virus in India.

We expect TML (standalone as well as JLR) to be among the hardest hit in our coverage universe given its exposure to various global markets and weak CV industry demand prospects domestically. For domestic operations, we build in volume growth of -31%, -5%, 10% for FY20E, FY21E, FY22E, respectively. On the JLR front, we build in volume growth of -7.1%, -3.3%, 9.3% for FY20E, FY21E, FY22E, respectively. In the present uncertain times for the domestic CV space and global luxury car market, we continue to assign **HOLD** rating on the stock with a revised target price of ₹ 85.

JLR's China February retail volumes were down 85% YoY

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-22E)
Net Sales	2,94,619.2	3,01,938.4	2,62,264.4	2,60,318.8	2,86,254.1	4.5%
BITDA	38,058.3	29,794.8	25,802.0	30,101.2	37,492.1	20.5%
BITDA Margins (%)	12.9	9.9	9.8	11.6	13.1	
Net P ro fit	9,091.4	(28,724.2)	(3,310.4)	(901.2)	3,490.7	NN
:PS (₹)	26.8	(84.6)	(9.1)	(2.4)	9.1	
P/E	2.8	(0.9)	(8.3)	(31.9)	8.2	
RoNW (%)	10.3	7.1	(0.0)	2.6	9.3	
RoCE (%)	9.1	5.4	4.6	5.7	8.5	

# Bajaj Auto (BAL)

BAL has closed manufacturing plants at Akurdi, Waluj, Chakan and Pantnagar till further notice. Its erstwhile domestic outperformance has been arrested significantly in recent months with domestic volumes now trending in line with industry. BAL's exports exposure, however, continues to place it above the industry on an overall basis. Given the sharp slide in crude oil prices, demand in key oil-dependent export economies like Nigeria is seen turning softer in coming months although rupee depreciation is in BAL's favour. Back home, BAL has argued against relaxation in BS-IV registration deadline, with its stock position comfortably placed in the run up to the switchover.

For BAL, we build in -40%, -10%, 6.6% YoY volume trajectory over FY20E, FY21E, FY22E, respectively. The valuation parameters, however, are within our comfortable range. Therefore, we retain our **BUY** rating on the stock with a target price of ₹ 2500, valuing the core operations at 15x P/E on FY22E numbers. We also drive comfort from capital efficient operations at BAL & >5% FCF yield.

The company has affirmed that while it is prepared for a halt of as long as eight weeks, it would stand by in support of employees in matters of pay as well as job security

For Bajaj Auto, in FY21E, the volume decline is expected to be the steepest in our coverage universe courtesy high exposure to exports. We expect volumes to rebound to ~45 lakh units in FY22E vs. ~47 units to be clocked in FY20E

K ey Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-22E)
Net Sales	25,164.9	30,250.0	30,021.9	29,986.2	32,139.3	3.59
E B IT D A	4,783.4	4,982.0	4,949.5	4,480.4	4,918.6	-0.39
EBITDA Margins (%)	19.0	16.5	16.5	14.9	15.3	
Net P rofit	4,068.1	4,675.1	4,742.1	4,236.8	4,588.8	-1.69
EPS(₹)	140.6	161.6	163.9	146.4	158.6	
P/E	15.0	13.1	12.9	14.4	13.3	
RoNW (%)	21.5	19.9	21.2	17.4	17.2	
RoCE (%)	22.9	21.0	20.5	22.6	22.5	

Source: Company, ICICI Direct Research

SOTP Valuation	Estimated value	Per share (₹)	er share (₹) Remark					
C ore Business								
FY22E EPS (₹)	158.6							
Multiple (x)	15.0		10% avera	discount ige	to	its	long	period
Value per share (₹)		2,377						
Stake in KTM (48%)								
KTM value derived back to Bajaj (₹ crore)	3660		3.0x	of Invested	Сар	ital (	₹1220	crore)
Value per share		125						
Total Value per Share (₹)		2,500						

Source: ICICI Direct Research

### Ashok Leyland (ALL)

ALL's BS-IV inventory has been nearly extinguished and was at ~600 units as of the first half of March. This places the company in a comfortable position as far as the immediate impact of nationwide lockdowns is concerned. The company recently said production activities in China have started returning on track, which eases some concerns around supply of crucial BS-VI components to which ALL has indirect exposure, like fuel injection pumps. BS-VI production is expected to ramp up quite gradually, as the market adjusts to the pricing of new products (7-15% hike over BS-IV) in a depressed demand environment as structural and cyclical factors impacting the CV industry (and M&HCV in particular) remain in place. For ALL, LCV segment is an area of focus towards its stated intention of breaking into the top 10 CV players globally - and the company would be retaining capex plans here even as it focuses on costs and capex spend rationalisation in other areas. Going forward, we expect its product mix to evolve in favour of buses and LCVs.

For ALL, we build in -32%, -1%, 10% YoY volume trajectory over FY20E, FY21E, FY22E, respectively. However, we upgrade the stock to **BUY** given that the company has acted prudently by reconsidering its recent investment decision in its subsidiary i.e. Hinduja Leyland Finance (HLF). Choosing to retain  $\sim$  ₹ 800 crore on books improves the company's balance sheet position during the ongoing challenging business conditions. We value ALL at ₹ 55/share, valuing its base business at 6.5x EV/EBITDA on FY22E numbers and assigning 40% holding company discount to 1.5x P/BV on its investment book (largely HLF).

We expect ALL to clock total sales volume of ~1.5 lakh units in FY22E vs. ~1.35 lakh units in FY20E and 1.97 lakh units in FY19. ALL's return ratios are seen returning to its double digit mark In FY22E as the sales prospects improve at the company

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY19-22E)
Net Sales	26,356.4	29,055.0	18,403.1	19,665.5	22,587.7	-8.0%
E B IT D A	2,963.5	3,135.7	1,222.5	1,420.4	2,027.1	-13.4%
EBITDA Margins (%)	11.2	10.8	6.6	7.2	9.0	
Net P rofit	1,717.7	1,983.2	341.3	498.1	942.5	-21.8%
EPS (₹)	5.9	6.8	1.2	1.7	3.2	
P/E	7.7	6.7	38.7	26.5	14.0	
RoNW (%)	24.0	24.3	4.7	5.7	10.4	
RoCE (%)	27.8	26.9	6.0	7.0	11.9	

Source: Company, ICICI Direct Research

SOTP	
Target EV/EBITDA (x)	6.5
EBITDA (FY22E)	2,027.1
Net D ebt	601.2
Enterprise Value (₹ C rore)	13,176.4
Target Market cap C ore business (₹crore)	12,575.3
Value/Share (A)	44
Strategic Investments FY22E (₹ crore)	3,186.5
P/BV(x)	1.5
Total Value/Share post applying 40% Holdco. Discount (B)	11
Price target (₹, A +B)	55

Source: ICICI Direct Research

## Eicher Motors (EIM)

Royal Enfield and VECV have suspended all production activities till March 31. EIM is best placed among the 2-W pack in respect of BS-VI transition as it has already liquidated all BS-IV inventory by March 20, well before the stipulated deadline. This leads us to expect that the company would be able to weather the financial impact of Covid-19 in a relatively better manner (lower discounting, no threat of dealer support to liquidate unsold stock) during Q4FY20. While supply constraints are limited, demand side challenges remain for Royal Enfield. Exports performance is likely to be severely hampered in coming months given the global scale of the outbreak. Domestically, being a premium product, sluggishness in sales is expected to worsen as the economic impact of Covid-19 slows discretionary consumption further. On the CV side, while VECV has been faring better than peers on the volume front in recent months, soft demand conditions remain in place for the industry. Hence, we remain conservative in our estimates.

For the RE brand, post demand slump in FY20E (down 13.5% YoY), we build in another 5% YoY decline in FY21E and 10% YoY growth in FY22E. On the VECV front, building on the recent outperformance by the JV vs. the industry, we build in volume decline of 2% YoY in FY21E and rebounding growth of 10.6% YoY in FY22. We continue to assign a **HOLD** rating to Eicher Motors with a revised target price of ₹ 16,870 using SOTP valuation methodology, valuing the RE franchise at 20x P/E on FY22E numbers.

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-22E)
Net Sales	8,965.0	9,797.1	9,388.6	9,569.8	10,792.3	7.2%
E B IT D A	2,807.6	2,903.1	2,350.2	2,240.0	2,681.3	6.8%
EBITDA Margins (%)	31.3	29.6	25.0	23.4	24.8	
Net Profit	1,959.7	2,202.8	2,011.6	1,874.5	2,285.0	6.6%
EPS (₹)	718.9	808.1	737.9	687.6	838.2	
P/E	20.9	18.6	20.3	21.8	17.9	
RoNW (%)	29.9	24.8	19.1	15.6	16.4	
R o C E (%)	39.1	32.5	22.9	19.6	20.5	

Source: Company, ICICI Direct Research

	FY22E	Remarks
Two-wheeler business-Royal Enfield		
EPS (₹)	824	
Target PE multiple(x)	20.0	Valued RE business at 20x P/E on FY22E numbers
Per share value (₹)	16,474	
Target market cap (₹ crore)	44,909	
CV business-VECV`		
PAT	199	
Target PE multiple(x)	10.0	Valued VE-CV business at 10x P/E on FY22E numbers
Target market cap (₹ crore)	1,990	
C ontribution towards E ML	0.54	EML has 54.4% stake in VECV
Target market cap towards EML (₹ crore)	1,083	
Per share value-VECV Eicher (₹)	397	
Total target market cap (₹ crore)	45,992	
Per share value (₹ )	16,870	

### **Escorts**

Escorts has temporarily shut all its manufacturing facilities in Faridabad (Haryana) till March 31 at least. In our opinion, short-term Covid-19 related blip aside, the domestic tractor industry is set to perform better than the automotive industry over FY20 & FY21 on the back of expectations of healthy water table levels and the government's focus on rural incomes and announcements for rural infrastructure. Escorts has been gaining market share in the domestic tractor market amid good performance in traditionally stronger markets of North, Central and East India. We expect this trend to continue. The performance of the construction equipment segment, however, is seen as being subdued as a general pick-up in infrastructure activity is yet to pan out.

We have assumed 2.8% YoY tractor volume growth for FY21E, followed which tractor volumes are expected to grow 7% YoY in FY22E to ~1 lakh units vs. ~92,000 units in FY20E. We also build in profit from associates of the JV with Kubota for FY21-22E i.e. ₹ 3.8 crore in FY21E and ₹ 25.2 crore in FY22E. We continue to assign **HOLD** rating to Escorts with a target price of ₹ 740 using the SOTP valuation methodology.

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY19-22E)
Net Sales	4,995.1	6,196.4	6,015.6	6,275.8	6,946.8	3.9%
E BITD A	557.2	733.3	677.7	720.6	835.5	4.4%
EBITD A Margins (%)	11.2	11.8	11.3	11.5	12.0	
Net P rofit	344.8	484.9	472.8	557.0	660.9	10.9%
EPS (₹)	28.1	39.6	38.6	45.4	53.9	
P/E	24.0	17.1	17.5	14.9	12.5	
RoNW (%)	13.8	15.6	13.9	11.1	11.8	
RoCE (%)	21.0	21.7	17.7	14.5	14.9	

Source: Company, ICICI Direct Research

Exhibit 13: Valuation matrix for Escorts	
Particulars	Amount (₹)
FY22E EPS (₹/share, A)	54
P/E Multiple (x, B)	12.0
Value of Base Business (C =A*B)	646
No of Treasury Shares (crore)	2.1
Current Market Price (₹/share)	675
Value of Investments (₹ crore)	1,448
Holding company discount (%)	20
Revised value of Investments (₹ crore)	1,158
Contribution per share (₹/share, D)	93
Target Price (C +D)	740
Potential Upside (%)	10

# Exide Industries (EIL)

In step with business models that have a higher dependence on aftermarket sales, we expect EIL to be relatively better placed in terms of sensitivity to demand shocks caused by the Covid-19 outbreak. Being largely domestic-focused is a further positive for EIL. Thus far, it has announced closure of manufacturing facilities in most states till further notice in compliance with various directives issued by the central and local governments. We continue to prefer EIL in the automotive battery space over the medium to long term on account of its proactive steps on the lithium ion front as well as its relatively inexpensive valuations.

However, for EIL, given the correction in metal prices, its topline, in value terms, will tend to decline sharper than the OEM topline decline with scope for gross margin expansion as it tends to retain the RM benefits on aftermarket sales. We build in a topline decline of 13.2% YoY in FY21E and a rebound to the tune of 11.5% YoY growth in FY22E. We retain our **BUY** rating on EIL with a revised target price of ₹ 160 valuing the company on an SOTP basis.

We continue to like Exide given the debt free nature of its B/S, steady CFO ( $\sim$ 10%) & FCF yields ( $\sim$ 5%) and healthy return ratios (RoIC >25%)

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-FY22E
Net Sales	9,210.2	10,588.3	10,013.4	8,688.2	9,690.5	-1.69
E BITD A	1,240.8	1,411.3	1,384.9	1,196.1	1,426.8	1.59
EBITD A Margins (%)	13.5	13.3	13.8	13.8	14.7	
Net P rofit	668.4	844.0	802.2	646.5	799.7	-0.29
EPS (₹)	7.9	9.9	9.4	7.6	9.4	
P/E	16.5	13.1	13.8	17.1	13.8	
RoNW (%)	12.9	12.9	12.9	9.6	11.1	
RoCE (%)	19.0	18.4	16.4	12.8	14.7	

Source: Company, ICICI Direct Research

SOTP Valuation	Estimated value	Value per share	Remark
Standalone Business			
2-year forward EPS (FY22E)	9.4		
P/E Multiple	12.0		
Value per share (₹)		114	
Insurance business			
Value of Exide Life Insurance (₹ crore)	3606		1.5x FY19 Embedded Value
Value per share (₹)		42	
Value of subsidiaries (₹ crore)			***************************************
Value of smelting subsidiaries (₹)	288	3	2x P/B on invesement (FY19)
Total Value per Share (₹)		160	

## **Bharat Forge (BFL)**

Demand prospects remain challenging for BFL, particularly on the CV side both domestic and globally. In the industrial segment, exposure to oil & gas space would also be a cause for concern as long as crude oil prices remain depressed. BFL intimated that its domestic manufacturing facilities were shut from March 23 (eight days before originally planned) while production in facilities abroad would also be suspended by March 27, depending on the specific geography. The company currently plans to resume production by mid-April. For BFL, the long term focus remains on de-risking its business model via continued shift away from the CV space towards PV and new-age including opportunities aluminium lightweighting, electric/hybrid mobility. We have a positive view on the company's approach towards diversification (products as well as geographies) and its focus on conserving cash at this juncture. However, we await a turning of the CV demand cycle to revisit our stance meaningfully on BFL.

We factor in total revenues declining 5% YoY in FY21, post a sharp decline of ~20%+ in FY20E. For FY22E, we build in steady state demand recovery with consolidated sales growing at 10% YoY. We retain our **HOLD** rating on BFL, valuing the company at ₹ 320 i.e. 25x P/E on FY22E numbers.

For Bharat Forge, the recovery can be delayed courtesy high exposure to domestic as well as global CV cycle as well exposure to industrials including US oil & gas segment

Key Financials	FY18	FY19	FY20E	FY21E	FY22E	CAGR (FY20E-22E)
Net Sales	8,357.7	10,145.7	8,014.7	7,642.7	8,416.5	2.59
E B IT D A	1,723.0	2,055.6	1,175.8	997.3	1,330.9	6.4%
EBITD A Margins (%)	20.6	20.3	14.7	13.0	15.8	
Net Profit	754.0	1,032.6	507.2	330.8	597.0	8.5%
EPS (₹)	16.2	22.2	10.9	7.1	12.8	
P/E	17.6	12.8	26.2	40.1	22.2	
RoNW (%)	17.3	19.1	9.4	5.8	9.9	
RoCE (%)	17.8	13.2	16.6	17.6	8.4	

Source: Company, ICICI Direct Research

# **Apollo Tyres**

Apollo Tyres (ATL) has suspended all manufacturing activity domestically at plants in Kerala, Gujarat, Tamil Nadu till March 31. For tyre players, while replacement channel would also be impacted in the short-term, overall demand scenario is expected to be relatively resilient due to limited exposure to the OEM channel (~30-35% of sales). Risks at ATL, however, are two-fold, as major European OEMs have also announced suspension of production activities amid the virus outbreak. Europe accounts for ~30% of consolidated ATL revenues, with ATL having a manufacturing presence in the Netherlands and Hungary. We anticipate operating and profit margins remaining under greater pressure in Q4FY20, Q1FY21E courtesy negative operating leverage and elevated outgo on interest and depreciation.


As a gesture of solidarity in these troubled times, the senior management has undertaken a voluntary reduction in pay of 15-25%


We incorporate issuance of CCPS and corresponding conversion to equity shares in our financial model





We build in nearly flat topline CAGR for ATL over FY20-22E. We continue to assign **HOLD** rating to the stock with a revised target price of ₹ 90 valuing the company at 4.5x EV/EBITDA on FY22E numbers.


Key Financials	FY18	FY19	FY20E	FY21E		CAGR (FY20E-22E)
Net Sales	14,840.5	17,548.8	16,692.1	15,232.2	16,963.2	0.8%
EBITDA	1,651.3	1,958.9	1,904.4	1,882.0	2,180.8	7.0%
EBITDA Margins (%)	11.1	11.2	11.4	12.4	12.9	
Net P rofit	723.9	680.0	455.5	210.6	445.0	-1.2%
EPS (₹)	12.7	11.9	8.0	3.7	7.0	
P/E	6.7	7.2	10.7	23.1	12.1	
RoNW (%)	7.4	8.3	4.4	1.9	3.8	
RoCE (%)	7.7	8.0	4.7	4.1	5.7	






















# RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%;

Hold: -5% to 15%; Reduce: -5% to -15%;

Sell: <-15%





Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com





### ANALYST CERTIFICATION

I/We, Shashank Kanodia, CFA, MBA (Capital Markets), and Jaimin Desai, CA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number — INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.